OssDsign AB (publ)

Hello and welcome to today's webcast with Osterstein. We're CEO Morten Henneveld and CFO Anders Svensson will present the report for the first quarter of 2025. After the presentation there will be a Q&A, so if you have any questions you can send them in via the form to the right. And with that said, I hand over the word to you guys.

Thank you.

Thank you and welcome. Good morning everyone. My name is Morten Henneveld. I'm the CEO of Osterstein. As always, I have our CFO Anders Svensson with me, and today we want to walk you through our first quarter results. But we've also come a very long way in a short amount of time with our clinical evidence and publications, so today's call will also put some extra emphasis on that. As always, when we do these presentations, the normal disclaimer. If we look at the highlights of the first quarter, then Firstly, we continue to see strong growth and we follow the same trajectory as in the previous quarters. Secondly, as can be witnessed by the numbers, we continue to see more and more operating leverage in this quarter and we are showing by far the best underlying result in the history of the company. Thirdly, Also, as in previous quarters, we continue to see a very healthy development in the strong fundamentals with further access in the US market, so more and more approvals, increasing customer base, as well as more usage of Ocetan Catalyst within those accounts. And last, but certainly not least, just after the quarter ended, we came out with an additional two publications one preclinical study showing best-in-class potency of osteosin catalyst, and we also came out with a long-term follow-up on our top fusion study showing 100% fusion rate. I will now hand you over to Anders to walk you through the financial results for the quarter before I come back and spend some more time on our clinical programs and evidence.